Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide | Zendy

Shinya Fujisawa | Zendy; Ryuzo Ohno | Zendy; Kazuyuki Shigeno | Zendy; Naruhiko Sahara | Zendy; Satoki Nakamura | Zendy; Kensuke Naito | Zendy; Miki Kobayashi | Zendy; Kaori Shinjo | Zendy; Akihiro Takeshita | Zendy; Yoshinari Suzuki | Zendy; Hisakuni Hashimoto | Zendy; Kenji Kinoshita | Zendy; Masahito Shimoya | Zendy; Toshikazu Kaise | Zendy; Kazunori Ohnishi | Zendy

Open Access

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

Author(s) -

Shinya Fujisawa,

Ryuzo Ohno,

Kazuyuki Shigeno,

Naruhiko Sahara,

Satoki Nakamura,

Kensuke Naito,

Miki Kobayashi,

Kaori Shinjo,

Akihiro Takeshita,

Yoshinari Suzuki,

Hisakuni Hashimoto,

Kenji Kinoshita,

Masahito Shimoya,

Toshikazu Kaise,

Kazunori Ohnishi

Publication year - 2006

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-006-0288-4

Subject(s) - arsenic trioxide , arsenic , urine , chemistry , pharmacokinetics , acute promyelocytic leukemia , pharmacology , cmax , metabolite , oral administration , excretion , medicine , biochemistry , retinoic acid , organic chemistry , gene

To investigate the pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO) at a daily dose of 0.15 mg/kg.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research